Transaction DateRecipientSharesTypePriceValue
19th November 2020John Purpura1,600Open or private purchase$12.68$20,288.00
17th November 2020Steven A J Salamon2,500Open or private purchase$12.11$30,280.00
17th November 2020Advisors, Inc. Rosalind2,500Open or private purchase$12.11$30,280.00
16th November 2020Gil Aharon2,000Open or private purchase$12.00$24,000.00
13th November 2020Steven A J Salamon2,000Open or private purchase$11.51$23,020.00
13th November 2020Advisors, Inc. Rosalind4,000Open or private purchase$11.75$47,000.00
10th September 2020Jennifer K. Simpson1,000Open or private purchase$2.74$2,737.10
1st September 2020Jennifer K. Simpson2,424Open or private purchase$0.00
8th May 2020Jennifer K. Simpson14,700Conversion of derivative$0.00
8th May 2020John Purpura6,500Conversion of derivative$0.00
Delcath Systems
Delcath Systems logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection.

Ticker: DCTH
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 872912
Employees: 33
Exchange: NASDAQ
Auditor Opinion:Going Concern

Disclosure Language changes
Red Flags